Authors' reply [0.03%]
作者回复
Sudeep Gupta,Rajendra A Kerkar,Rajesh Dikshit et al.
Sudeep Gupta et al.
Joel Palefsky
Joel Palefsky
Lucy A Pickard,Graham Knee,Vishal Jayakar
Lucy A Pickard
Using 2(nd) generation tyrosine kinase inhibitors in frontline management of chronic phase chronic myeloid leukemia [0.03%]
二代酪氨酸激酶抑制剂一线治疗慢性期慢性粒细胞白血病中的应用
Vishal Jayakar
Vishal Jayakar
Choices in medicine come with responsibility. With several TKI's (Tyrosine kinase inhibitors) available for front-line management of CML (Chronic Myeloid Leukemia), an astute clinician has to personalise, rationalise and take a pragmatic ap...
Is imatinib still the best choice as first-line oral TKI [0.03%]
伊马替尼作为初治慢性髓性白血病口服酪氨酸激酶抑制剂的一线治疗是否仍然最佳？
Shweta Bansal
Shweta Bansal
Targeted therapy is the buzz word these days. A decade back the emergence of tyrosine kinase inhibitor Imatinib on the horizon, as the targeted therapy, had captured the imagination of everyone in the field of cancer. It is encouraging to s...
Jay Halbert,Aye Aye Khaing
Jay Halbert
Myanmar is a country in southeast Asia in political, economic and healthcare transition. There are currently only two pediatric oncology centers serving a population of almost 19 million children. An estimated 85-92% of children with cancer...
K C Lakshmaiah,B Guruprasad,K N Lokesh et al.
K C Lakshmaiah et al.
In many developed countries, notification of cancer cases is compulsory. Developing countries including India accounts for more than half of new cancer cases in the world, however notification of cancer is not yet mandatory. The primary pur...
Lalit S Raut,Prantar P Chakrabarti
Lalit S Raut
Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating...
Late effects of treatment in survivors of childhood cancer from a tertiary cancer center in South India [0.03%]
印度南部三级癌症中心儿童肿瘤幸存者的治疗远期反应
Rejiv Rajendranath,Surendran Veeraiah,Anita Ramesh et al.
Rejiv Rajendranath et al.
Background: Improved survival after childhood cancer is attributed to intensive, aggressive therapy, adverse sequelae of which can manifest months to years after completion of treatment. There is little information about ...